Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Feb 13, 2026
MUFG vs HSBC Stock Comparison: Earnings Preview Amid Global Banking Shifts

MUFG vs HSBC Stock Comparison: Earnings Preview Amid Global Banking Shifts

Key Takeaways

  • MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion.

  • HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.

  • MUFG reaffirmed FY2026 profit guidance of ¥2.1 trillion, boosted by strong domestic lending and Morgan Stanley equity earnings.

  • Both banks maintain strong capital positions: MUFG equity-to-asset ratio ~5.1%, HSBC CET1 ~14.5% YTD.

  • MUFG benefits from Japanese rate hikes, while HSBC leverages Asian wealth management amid global trade uncertainties.

  • Recent stock performance: MUFG ADR up ~20% over the past year; HSBC remains stable with dividend appeal.

Earnings Context: Why This Comparison Matters

MUFG, Japan’s largest bank by assets, approaches its FY2026 full-year results in May 2026 after a strong nine-month performance. Investors are monitoring progress toward its ambitious ¥2.1 trillion profit target, supported by rising Japanese loan demand and overseas contributions.

Comparing MUFG with HSBC, a global banking powerhouse with heavy Asia exposure, highlights differences in regional dynamics: MUFG’s Japan-centric strength versus HSBC’s diversified international banking and wealth operations. Both banks face interest rate shifts, trade tensions, and credit risks, making this a critical matchup for assessing resilient global banking plays in an uncertain environment.

MUFG Earnings Focus

  • Quarter: Q3 FY2026 (nine months ended Dec 31, 2025)

  • Profits attributable to owners: ¥1.81 trillion (+3.7% YoY, ~$12B)

  • Ordinary income: ¥10.64 trillion (+3.6%)

  • Basic EPS: ¥158.89

  • Key drivers: Lower credit costs, strong Morgan Stanley equity earnings

  • FY2026 guidance: Profits reaffirmed at ¥2,100 billion, reflecting confidence in H2 loan growth and margins from Bank of Japan policy normalization.

  • Historical trend: MUFG consistently beats EPS estimates (e.g., Q3 $0.29 vs $0.28; Q2 $0.42 vs $0.31), with shares reacting positively to guidance.

  • Capital metrics: Risk assets stable, CET1 ~10–10.5%

  • Next full-year results: Expected May 2026

HSBC Context and Earnings Relevance

  • Upcoming earnings: Q4 FY2025 (full year Dec 31, 2025) on Feb 25, 2026

  • Consensus EPS: ~$1.60

  • Recent performance: Q3 revenue ~$17.9B; annualized RoTE 16.4% (17.6% YTD ex-notables); wealth fees +29%; deposits +$86B to $1.7T

  • Management upgrades: Banking NII to $43B+ and RoTE to mid-teens

  • Key metrics: CET1 ~14.5%, impact of Hang Seng privatization, cost savings target $1.5B by 2026

  • Historical volatility: EPS surprises mixed; recent core operations remain strong despite provisions

  • Growth drivers: Asia wealth inflows, efficiency initiatives

Head-to-Head Earnings and Market Comparison

  • MUFG: FY2026 nine-month profits of ¥1.81T driven by domestic NII gains (yield spread ~0.95%) and overseas loans; Morgan Stanley contribution >25% of earnings.

  • HSBC: Q3 revenue stable; Asia wealth inflows ~$29B net new; legal provisions introduce volatility.

  • Risks: MUFG exposed to Japanese rates and equity markets; HSBC to China commercial real estate and trade tensions.

  • Capital strength: Both banks solid; MUFG’s Japan focus may deliver higher ROA, HSBC offers global diversification.

  • Investor sentiment: MUFG favored for consistent EPS beats; HSBC’s upgrades signal resilience amid mixed quarters.

  • Strategic trade-off: MUFG suited for yield-focused investors; HSBC for international exposure and portfolio diversification.

AI Trading Bot Perspective

Tickeron’s Trend Trader for Beginners Strategy for Large-Cap Stocks (60-min TA) uses 60-minute technical analysis to track momentum in large-cap stocks like HSBC. Backtested on volatile markets, it identifies entry and exit points based on momentum indicators, helping investors navigate banking sector trends.

Tickeron AI Verdict:

  • Near-term edge leans toward MUFG, thanks to consistent EPS performance, reaffirmed profit targets, and stable Japan banking trends.

  • HSBC shows strong operational upgrades but provisions introduce volatility.

  • Both banks remain suitable for diversified portfolios; MUFG offers short-term stability, HSBC offers long-term international exposure.

Disclaimers and Limitations

Related Ticker: MUFG, HSBC

MUFG's RSI Indicator recovers from overbought zone

The 10-day RSI Indicator for MUFG moved out of overbought territory on July 28, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 instances where the indicator moved out of the overbought zone. In of the 42 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 68 cases where MUFG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on August 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MUFG as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for MUFG turned negative on July 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MUFG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MUFG broke above its upper Bollinger Band on July 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MUFG advanced for three days, in of 345 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 310 cases where MUFG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 20, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MUFG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.742) is normal, around the industry mean (1.938). P/E Ratio (16.206) is within average values for comparable stocks, (16.226). Projected Growth (PEG Ratio) (1.859) is also within normal values, averaging (1.631). Dividend Yield (0.025) settles around the average of (0.025) among similar stocks. P/S Ratio (5.211) is also within normal values, averaging (4.327).

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), Bank of America Corp (NYSE:BAC), HSBC Holdings PLC (NYSE:HSBC), Wells Fargo & Co (NYSE:WFC), Citigroup (NYSE:C), Barclays PLC (NYSE:BCS).

Industry description

Major banks are among the biggest companies in the world, often times with global reach and market capitalizations in the multi-billions. Large banks often have multiple arms spanning different disciplines, from deposits, to investment banking, to wealth management and insurance. The biggest banks often have key competitive advantages over smaller players in the industry in terms of brand recognition, cost of capital, and efficiency. Think J.P. Morgan, Bank of America, Wells Fargo, and Citigroup.

Market Cap

The average market capitalization across the Major Banks Industry is 216.86B. The market cap for tickers in the group ranges from 1.04M to 950.36B. JPM holds the highest valuation in this group at 950.36B. The lowest valued company is BACRP at 1.04M.

High and low price notable news

The average weekly price growth across all stocks in the Major Banks Industry was 1%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 20%. ING experienced the highest price growth at 6%, while SMFG experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the Major Banks Industry was 3%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 67
P/E Growth Rating: 30
Price Growth Rating: 39
SMR Rating: 8
Profit Risk Rating: 19
Seasonality Score: -22 (-100 ... +100)
View a ticker or compare two or three
MUFG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a major bank

Industry MajorBanks

Profile
Details
Industry
Major Banks
Address
7-1, Marunouchi 2-Chome
Phone
+81 332408111
Employees
149700
Web
https://www.mufg.jp
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.